IGF-1 growth factor testing is a quantitative laboratory assay that measures insulin-like growth factor 1 (somatomedin C) in blood to evaluate growth hormone axis activity and related endocrine disorders. As a stable surrogate marker of integrated growth hormone secretion, IGF-1 plays a central role in the diagnosis of growth hormone deficiency, acromegaly, gigantism, and pediatric short stature. This technical guide covers the biological basis, sample requirements, analytical methods, clinical applications, and frequently asked questions related to IGF-1 testing.
Technical Overview
Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a 70-amino acid single-chain polypeptide hormone with a molecular weight of approximately 7.6 kDa. Structurally homologous to proinsulin, IGF-1 is produced primarily by hepatocytes in response to pulsatile stimulation by growth hormone (GH) released from the anterior pituitary gland. Although GH is the primary regulator, IGF-1 mediates most of the anabolic and growth-promoting effects of the GH axis, including longitudinal bone growth, protein synthesis, cell proliferation, and glucose metabolism.
In the systemic circulation, more than 99% of IGF-1 is bound to a family of six high-affinity insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), predominantly IGFBP-3 and the acid-labile subunit (ALS). This ternary complex extends the circulating half-life of IGF-1 to approximately 15 to 20 hours, in contrast to the short half-life of GH of roughly 15 to 30 minutes. Because GH secretion is highly pulsatile and strongly influenced by sleep, exercise, stress, and nutrition, a single random GH measurement has limited diagnostic value. IGF-1, by comparison, integrates GH secretory activity over the preceding 24 to 48 hours, making it the recommended first-line laboratory marker for assessing GH axis status.
IGF-1 concentrations are physiologically dependent on several variables that must be considered during interpretation:
- Age: levels rise gradually through childhood, peak during puberty, and decline progressively with advancing age.
- Sex and pubertal stage: pubertal peaks differ between males and females.
- Nutritional status: protein-energy malnutrition and prolonged fasting suppress hepatic IGF-1 synthesis.
- Hepatic function: severe liver disease reduces IGF-1 production.
- Endocrine and metabolic factors: hypothyroidism, uncontrolled diabetes mellitus, oral estrogen therapy, renal failure, and pregnancy can all alter circulating levels.
Because of this biological variability, IGF-1 results must always be interpreted against age-specific and sex-specific reference intervals established for the specific analytical platform in use.
Testing Samples
Serum
Serum is the standard and most widely accepted sample type for IGF-1 measurement. A venous blood specimen of 2 to 5 mL is collected into a plain tube or serum separator tube and allowed to clot before centrifugation. IGF-1 is relatively stable in serum; samples can typically be stored at 2 to 8°C for up to several days, or frozen at -20°C or below for long-term storage. Repeated freeze-thaw cycles should be avoided.
Plasma
Plasma collected into EDTA or lithium heparin anticoagulant tubes may be acceptable for certain automated immunoassay and LC-MS/MS platforms. Acceptability of plasma depends on the assay manufacturer's validated sample matrix, and laboratories should verify performance characteristics before substituting plasma for serum.
Dried Blood Spots
Dried blood spot (DBS) sampling is used in selected research protocols, pediatric studies, and population-level screening projects. DBS offers minimal invasiveness and simplified logistics for transport and storage, although method validation is required to ensure agreement with conventional serum-based measurements.
Testing Items
The core deliverable of an IGF-1 test is the quantitative concentration of total IGF-1 in serum or plasma, reported in ng/mL or converted to nmol/L using the conversion factor 1 ng/mL = 0.131 nmol/L. Total IGF-1 refers to the sum of all IGF-1 released from its binding proteins during the analytical pretreatment step. The report typically includes:
- Measured total IGF-1 concentration (ng/mL or nmol/L).
- Age-specific and sex-specific reference interval applicable to the assay platform.
- A standard deviation score (SDS) or Z-score for pediatric patients, calculated against normative growth reference data.
- Interpretive comments from the laboratory, where clinically appropriate.
Depending on the clinical question, IGF-1 measurement is frequently combined with related analytes of the GH axis, including IGFBP-3, acid-labile subunit, and dynamic GH stimulation or suppression testing, to construct a complete endocrine evaluation.
Testing Methods
Sample Pretreatment and Release from Binding Proteins
A critical pre-analytical step in virtually all IGF-1 assays is the dissociation of IGF-1 from its high-affinity binding proteins. This is commonly achieved through acidification or acid-ethanol extraction, sometimes followed by neutralization and dilution. Effective pretreatment prevents IGFBP interference and cross-reactivity, which historically caused substantial inaccuracy and underestimation of IGF-1 concentrations.
Immunoassays
Automated immunoassays are the dominant methodology in routine clinical laboratories:
- Chemiluminescent immunoassay (CLIA) and electrochemiluminescent immunoassay (ECLIA): sandwich-format assays performed on high-throughput automated analyzers, offering excellent precision, short turnaround times, and broad age-calibrated reference ranges.
- Enzyme-linked immunosorbent assay (ELISA): plate-based sandwich assays widely used in research laboratories and lower-volume settings; ELISA provides good analytical sensitivity at lower equipment cost but with longer hands-on time and greater susceptibility to inter-operator variability.
- Immunoradiometric assay (IRMA): an earlier generation method, now largely replaced by non-isotopic platforms.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
LC-MS/MS is increasingly regarded as the reference-grade methodology for IGF-1 quantification. Following protein precipitation or immunoextraction and tryptic digestion, signature peptides of IGF-1 are quantified by multiple reaction monitoring against stable isotope-labeled internal standards. LC-MS/MS offers superior analytical specificity, minimal susceptibility to binding protein interference and heterophile antibody effects, and improved inter-laboratory comparability, making it valuable for standardization programs and complex diagnostic cases.
Quality Control and Standardization
Laboratories should calibrate assays against recognized international standards, such as the WHO NIBSC reference preparation 02/254, and participate in external quality assessment schemes. Internal quality control materials at low, medium, and high concentrations should be run with each batch, and method-specific reference intervals must be verified or established locally, since bias between platforms can be clinically significant.
Applications
Growth Hormone Deficiency
A persistently low IGF-1 level that falls below the age-adjusted reference interval provides strong supportive evidence for GH deficiency in both children and adults. Because IGF-1 alone is neither fully sensitive nor fully specific, diagnosis is confirmed with dynamic GH stimulation testing using pharmacologic agents such as insulin tolerance testing, glucagon, arginine, clonidine, or GHRH-arginine combinations. IGF-1 is also central to diagnosing congenital IGF-1 deficiency and GH insensitivity syndromes such as Laron syndrome.
Acromegaly and Gigantism
Elevated IGF-1 is the single best biochemical screening marker for GH excess. In suspected acromegaly, an age-elevated IGF-1 concentration prompts confirmatory testing with an oral glucose load, in which failure of GH to suppress below defined thresholds confirms autonomous GH secretion. Serial IGF-1 measurements are the mainstay of post-treatment monitoring following transsphenoidal surgery, medical therapy with somatostatin analogs or GH receptor antagonists, or radiotherapy.
Pediatric Growth Assessment
IGF-1 measurement, reported as an SDS relative to age and pubertal stage, is a routine component in the evaluation of short stature, growth deceleration, and suspected hypopituitarism in children. It helps differentiate endocrine growth failure from constitutional, nutritional, or genetic causes and guides the decision to pursue further pituitary imaging or provocative GH testing.
Treatment Monitoring and Dose Titration
In patients receiving recombinant human GH replacement therapy, IGF-1 is monitored at regular intervals to titrate the dose toward a target range, generally the middle to upper half of the age-appropriate reference interval, while avoiding overtreatment and associated adverse effects such as edema, arthralgia, and potential long-term metabolic risk.
Anti-Doping Analysis
IGF-1 is included in the athlete biological passport framework of the World Anti-Doping Agency as a biomarker of GH abuse, typically measured in combination with markers of collagen turnover such as P-III-NP. Longitudinal monitoring of these markers improves detection of exogenous GH administration, which suppresses and is otherwise difficult to identify through direct measurement.
Nutritional, Metabolic, and Research Applications
Beyond classical endocrinology, IGF-1 serves as a sensitive marker of protein-energy nutritional status and hepatic synthetic function, and it is extensively used in clinical research on aging, sarcopenia, metabolic syndrome, chronic kidney disease, and endocrine disruption.
FAQ
Is fasting required before IGF-1 testing?
Fasting is not strictly required because IGF-1 exhibits minimal diurnal variation compared with GH. However, morning collection is recommended for consistency, and some laboratories prefer fasting specimens, particularly when the same sample will be used for complementary metabolic testing.
What does an elevated IGF-1 result mean?
An elevated IGF-1 level suggests GH excess and raises suspicion of acromegaly in adults or gigantism in children with open growth plates. Confirmation requires an oral glucose GH suppression test and pituitary imaging. Other contributors, such as late adolescence, should be excluded through age-matched reference ranges.
What does a low IGF-1 result mean?
A low IGF-1 level may indicate GH deficiency, hypopituitarism, GH receptor insensitivity, protein-calorie malnutrition, chronic liver disease, hypothyroidism, or poorly controlled diabetes. It may also simply reflect the normal age-related decline. Low results should be correlated with clinical findings and confirmed with GH stimulation testing where appropriate.
Why is IGF-1 tested instead of growth hormone directly?
GH is secreted in pulses with a very short plasma half-life, so a single random GH value cannot reliably distinguish normal from deficient or excess states. IGF-1 is stable, has a long half-life, and reflects the integrated GH secretory activity of the previous one to two days, providing a far more robust screening and monitoring marker.
How long does it take to receive IGF-1 test results?
On automated immunoassay platforms, results are typically available within one to three working days. Specimens referred to specialized or mass spectrometry laboratories may require several additional days.
Are IGF-1 reference ranges the same for everyone?
No. Reference intervals vary substantially by age, sex, and pubertal stage, and they also differ between assay platforms and laboratories. Results must always be interpreted using the reference ranges validated for the specific method that performed the analysis.
Can medications affect IGF-1 results?
Yes. Oral estrogen administration suppresses hepatic IGF-1 production, recombinant GH therapy raises IGF-1, and agents such as high-dose glucocorticoids, somatostatin analogs, and GH receptor antagonists modify the GH-IGF axis. Clinicians should document all relevant medications when ordering the test.